The tweet was deleted by the author.
But we saved everything 🙂.
Myriad Genetics has introduced an updated version of its test specifically designed for active surveillance, now enhanced with artificial intelligence capabilities.
The company urges healthcare providers to tailor active surveillance management for patients using this AI-powered solution. The new offering targets the fields of urology and prostate cancer, leveraging genetic insights to improve early detection and monitoring. The move underscores Myriad Genetics’ commitment to advancing genetic testing in clinical practice.
Earlier, Myriad Genetics announced the launch of its Prolaris plus AI test, combining molecular scores with digital pathology for prostate cancer diagnosis. The company has also introduced its Precise MRD test for advanced molecular residual disease detection. These efforts highlight Myriad’s continued focus on integrating AI and molecular insights into clinical testing.